BIXINK OC Free for Obsessive-Compulsive Disorder

Phase-Based Progress Estimates
Obsessive-Compulsive Disorder+3 More
BIXINK OC Free - Device
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new app to help people with OCD who are also receiving outpatient therapy. The app provides treatment via computerized exposure and response prevention, and the trial will evaluate its safety and effectiveness.

Eligible Conditions
  • Obsessive-Compulsive Disorder
  • Obsessive compulsive behavior

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Obsessive-Compulsive Disorder

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Endpoint (week 6), Follow-up (week 10)

Week 10
Clinical Global Impression - Improvement scale (CGI-I)
Week 10
Beck Anxiety Inventory
Mental Depression
Clinical Global Impression-Severity Scale (CGI-S)
Yale-Brown Obsessive-Compulsive Scale (Y-BOCs)

Trial Safety

Safety Progress

1 of 3

Other trials for Obsessive-Compulsive Disorder

Trial Design

1 Treatment Group

1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: BIXINK OC Free · No Placebo Group · N/A

Experimental Group · 1 Intervention: BIXINK OC Free · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: endpoint (week 6), follow-up (week 10)

Who is running the clinical trial?

BIXINK Therapeutics Co., Ltd.Lead Sponsor
Eric Hollander, MDPrincipal InvestigatorSpectrum Neuroscience and Treatment Institute
16 Previous Clinical Trials
631 Total Patients Enrolled
2 Trials studying Obsessive-Compulsive Disorder
187 Patients Enrolled for Obsessive-Compulsive Disorder

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are currently engaged in formal psychotherapy, ERP, prior to enrollment.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 21st, 2021

Last Reviewed: October 11th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
New York100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%